| 000 | 01622 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250514221044.0 | ||
| 264 | 0 | _c20050719 | |
| 008 | 200507s 0 0 eng d | ||
| 022 | _a0315-162X | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBradley, John D | |
| 245 | 0 | 0 |
_aA randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. _h[electronic resource] |
| 260 |
_bThe Journal of rheumatology _cMar 2005 |
||
| 300 |
_a417-23 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAcetates _xadverse effects |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadverse effects |
| 650 | 0 | 4 |
_aArthritis, Rheumatoid _xdrug therapy |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndoles _xadverse effects |
| 650 | 0 | 4 | _aKeto Acids |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPhospholipases A _xantagonists & inhibitors |
| 650 | 0 | 4 | _aPhospholipases A2 |
| 650 | 0 | 4 | _aPlacebos |
| 700 | 1 | _aDmitrienko, Alexei A | |
| 700 | 1 | _aKivitz, Alan J | |
| 700 | 1 | _aGluck, Oscar S | |
| 700 | 1 | _aWeaver, Arthur L | |
| 700 | 1 | _aWiesenhutter, Craig | |
| 700 | 1 | _aMyers, Stephen L | |
| 700 | 1 | _aSides, Gregory D | |
| 773 | 0 |
_tThe Journal of rheumatology _gvol. 32 _gno. 3 _gp. 417-23 |
|
| 999 |
_c15416394 _d15416394 |
||